Evaluating JAK and TNF Inhibitors: Safety and Innovations

This chapter examines a comprehensive Bayesian network meta-analysis assessing the risk of malignancy tied to JAK inhibitors and TNF inhibitors among patients with inflammatory diseases. Additionally, it highlights innovative treatments and technologies presented at ACR 2024, emphasizing their potential to enhance patient outcomes and the insights from ongoing studies on rheumatoid arthritis.

Transcript

Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app